The first patient has been enrolled in a U.S. clinical trial evaluating the efficacy and safety of a new artificial…
Articles by Vanda Pinto, PhD
Trevi Therapeutics announced that CANAL, its proof-of-concept Phase 2 trial evaluating Haduvio (nalbuphine extended-release tablets) for the treatment of…
Joint infection with a virus and bacteria in people with idiopathic pulmonary fibrosis (IPF) significantly raises their risk of…
Cudetaxestat (BLD-0409), an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed favorable safety and tolerability in a Phase 1…
With reasonable safety, Ofev (nintedanib) slowed lung function decline in Japanese patients with progressive fibrosing interstitial lung diseases (ILDs),…
Decline in lung function is slower in people with advanced idiopathic pulmonary fibrosis (IPF) who start treatment with Ofev…
Listening for fine crackles — a sound like Velcro strips being separated — during routine lung checks with a stethoscope…
Thirona Bio has teamed with MannKind Corporation to develop and test a potential inhaled treatment for fibrotic lung diseases,…
Nuformix announced it has received notice that it can expect to be granted a U.S. patent for its potential…
Rubedo Life Sciences announced that it has partnered with Cedars-Sinai Medical Center, also in California, to advance its…